{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T05:53:09Z","timestamp":1648533189532},"reference-count":75,"publisher":"Japanese Association of Virology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Uirusu"],"published-print":{"date-parts":[[2015]]},"DOI":"10.2222\/jsv.65.245","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T22:06:54Z","timestamp":1476828414000},"page":"245-254","source":"Crossref","is-referenced-by-count":0,"title":["Anti-hepatitis C virus strategy targeting host entry factor claudin-1"],"prefix":"10.2222","volume":"65","author":[{"given":"Masayoshi","family":"FUKASAWA","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1062","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Chung RT and Baumert TF: Curing chronic hepatitis C the arc of a medical triumph. N Engl J Med 370: 1576-1578, 2014.","DOI":"10.1056\/NEJMp1400986"},{"key":"2","unstructured":"2) Sarrazin C: The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol, 2015."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Soriano V, Vispo E, Poveda E, Labarga P and Barreiro P: Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 13: 313-323, 2012.","DOI":"10.1517\/14656566.2012.653341"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Donaldson EF, Harrington PR, O'Rear JJ and Naeger LK: Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61: 56-65, 2015.","DOI":"10.1002\/hep.27375"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Zeisel MB, Crouchet E, Baumert TF and Schuster C: Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses 7: 5659-5685, 2015.","DOI":"10.3390\/v7112898"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Baugh JM, Garcia-Rivera JA and Gallay PA: Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res 100: 555-561, 2013.","DOI":"10.1016\/j.antiviral.2013.09.020"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Fukasawa M: Claudin 1 as a target for anti-hepatitis C virus strategy. Yakugaku Zasshi 134: 635-640, 2014.","DOI":"10.1248\/yakushi.14-00006-4"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T and Chisari FV: Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294-9299, 2005.","DOI":"10.1073\/pnas.0503596102"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R and Liang TJ: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796, 2005.","DOI":"10.1038\/nm1268"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Fukasawa M, Nagase S, Shirasago Y, Iida M, Yamashita M, Endo K, Yagi K, Suzuki T, Wakita T, Hanada K, Kuniyasu H and Kondoh M: Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model. J Virol 89: 4866-4879, 2015.","DOI":"10.1128\/JVI.03676-14"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G and Abrignani S: Binding of hepatitis C virus to CD81. Science 282: 938-941, 1998.","DOI":"10.1126\/science.282.5390.938"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, Barth H, Baumert TF, Dubuisson J and Wakita T: CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol 81: 5036-5045, 2007.","DOI":"10.1128\/JVI.01573-06"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, Hatziioannou T, McKeating JA, Bieniasz PD and Rice CM: Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446: 801-805, 2007.","DOI":"10.1038\/nature05654"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, Schwarz A, Desombere I, Roels GL, Balfe P and McKeating JA: Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47: 17-24, 2008.","DOI":"10.1002\/hep.21959"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P and McKeating JA: Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 85: 596-605, 2011.","DOI":"10.1128\/JVI.01592-10"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM and Patel AH: CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 90: 48-58, 2009.","DOI":"10.1099\/vir.0.006700-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Furuse M, Fujita K, Hiiragi T, Fujimoto K and Tsukita S: Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141: 1539-1550, 1998.","DOI":"10.1083\/jcb.141.7.1539"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Gunzel D and Fromm M: Claudins and other tight junction proteins. Compr Physiol 2: 1819-1852, 2012.","DOI":"10.1002\/cphy.c110045"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Shirasago Y, Sekizuka T, Saito K, Suzuki T, Wakita T, Hanada K, Kuroda M, Abe R and Fukasawa M: Isolation and characterization of an Huh.7.5.1-derived cell clone highly permissive to hepatitis C virus. Jpn J Infect Dis 68: 81-88, 2015.","DOI":"10.7883\/yoken.JJID.2014.231"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C and Baumert TF: Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51: 1144-1157, 2010.","DOI":"10.1002\/hep.23445"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J and Baumert TF: Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139: 953-964, e4, 2010.","DOI":"10.1053\/j.gastro.2010.05.073"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Bartosch B, Dubuisson J and Cosset FL: Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197: 633-642, 2003.","DOI":"10.1084\/jem.20021756"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kikuchi R, McCown M, Olson P, Tateno C, Morikawa Y, Katoh Y, Bourdet DL, Monshouwer M and Fretland AJ: Effect of hepatitis C virus infection on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with humanized liver. Drug Metab Dispos 38: 1954-1961, 2010.","DOI":"10.1124\/dmd.109.031732"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FH, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lutgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E and Baumert TF: Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 33: 549-554, 2015.","DOI":"10.1038\/nbt.3179"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Zeisel MB, Felmlee DJ and Baumert TF: Hepatitis C virus entry. Curr Top Microbiol Immunol 369: 87-112, 2013.","DOI":"10.1007\/978-3-642-27340-7_4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Lindenbach BD and Rice CM: The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 11: 688-700, 2013.","DOI":"10.1038\/nrmicro3098"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Douam F, Lavillette D and Cosset FL: The mechanism of HCV entry into host cells. Prog Mol Biol Transl Sci 129: 63-107, 2015.","DOI":"10.1016\/bs.pmbts.2014.10.003"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Shi Q, Jiang J and Luo G: Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J Virol 87: 6866-6875, 2013.","DOI":"10.1128\/JVI.03475-12"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Lefevre M, Felmlee DJ, Parnot M, Baumert TF and Schuster C: Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E. PLoS One 9: e95550, 2014.","DOI":"10.1371\/journal.pone.0095550"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE and Baumert TF: Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278: 41003-41012, 2003.","DOI":"10.1074\/jbc.M302267200"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S and Thomssen R: Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 57: 223-229, 1999.","DOI":"10.1002\/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Agnello V, Abel G, Elfahal M, Knight GB and Zhang QX: Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 96: 12766-12771, 1999.","DOI":"10.1073\/pnas.96.22.12766"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R and Vitelli A: The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21: 5017-5025, 2002.","DOI":"10.1093\/emboj\/cdf529"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Jiang J, Wu X, Tang H and Luo G: Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors. PLoS One 8: e67982, 2013.","DOI":"10.1371\/journal.pone.0067982"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Chang KS, Jiang J, Cai Z and Luo G: Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol 81: 13783-13793, 2007.","DOI":"10.1128\/JVI.01091-07"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Jiang J and Luo G: Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol 83: 12680-12691, 2009.","DOI":"10.1128\/JVI.01476-09"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J and Protzer U: A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis 205: 1654-1664, 2012.","DOI":"10.1093\/infdis\/jis273"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Prentoe J, Serre SB, Ramirez S, Nicosia A, Gottwein JM and Bukh J: Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus. J Virol 88: 1725-1739, 2014.","DOI":"10.1128\/JVI.02017-13"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, Terce F, Duverlie G, Rouille Y and Dubuisson J: Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 55: 998-1007, 2012.","DOI":"10.1002\/hep.25501"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Dao Thi VL, Granier C, Zeisel MB, Guerin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL and Dreux M: Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem 287: 31242-31257, 2012.","DOI":"10.1074\/jbc.M112.365924"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Andreo U, Maillard P, Kalinina O, Walic M, Meurs E, Martinot M, Marcellin P and Budkowska A: Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. Cell Microbiol 9: 2445-2456, 2007.","DOI":"10.1111\/j.1462-5822.2007.00972.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Tao J, Kang KD, Hall SD, Laube AH, Liu J, Renfrow MB, Novak J and Luo G: The serum very-low-density lipoprotein serves as a restriction factor against hepatitis C virus infection. J Virol 89: 6782-6791, 2015.","DOI":"10.1128\/JVI.00194-15"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Liu S, Yang W, Shen L, Turner JR, Coyne CB and Wang T: Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 83: 2011-2014, 2009.","DOI":"10.1128\/JVI.01888-08"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Park JH, Park S, Yang JS, Kwon OS, Kim S and Jang SK: Discovery of cellular proteins required for the early steps of HCV infection using integrative genomics. PLoS One 8: e60333, 2013.","DOI":"10.1371\/journal.pone.0060333"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L and Baumert TF: EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17: 589-595, 2011.","DOI":"10.1038\/nm.2341"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Sainz B, Jr., Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA and Uprichard SL: Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 18: 281-285, 2012.","DOI":"10.1038\/nm.2581"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Martin DN and Uprichard SL: Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci U S A 110: 10777-10782, 2013.","DOI":"10.1073\/pnas.1301764110"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Masson D, Koseki M, Ishibashi M, Larson CJ, Miller SG, King BD and Tall AR: Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol 29: 2054-2060, 2009.","DOI":"10.1161\/ATVBAHA.109.191320"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, Amorosa V, Bhattacharya D, Coughlin K, Wong-Staal F, Glesby MJ and Team ACTGAP: Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis 209: 658-667, 2014.","DOI":"10.1093\/infdis\/jit503"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H and Leroux-Roels G: Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48: 1761-1768, 2008.","DOI":"10.1002\/hep.22547"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoel M, Leyssen P, Neyts J, Zeisel MB and Baumert TF: Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 64: 483-494, 2015.","DOI":"10.1136\/gutjnl-2013-306155"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Slowikowski MP, Fafi-Kremer S, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P and Nicosia A: Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol 57: 17-23, 2012.","DOI":"10.1016\/j.jhep.2012.02.018"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A and Meuleman P: Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology 60: 1508-1518, 2014.","DOI":"10.1002\/hep.27196"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Meyer K, Kwon YC, Liu S, Hagedorn CH, Ray RB and Ray R: Interferon-alpha inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection. Sci Rep 5: 9012, 2015.","DOI":"10.1038\/srep09012"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Zahid MN, Turek M, Xiao F, Thi VL, Guerin M, Fofana I, Bachellier P, Thompson J, Delang L, Neyts J, Bankwitz D, Pietschmann T, Dreux M, Cosset FL, Grunert F, Baumert TF and Zeisel MB: The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 57: 492-504, 2013.","DOI":"10.1002\/hep.26097"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Gondar V, Molina-Jimenez F, Hishiki T, Garcia-Buey L, Koutsoudakis G, Shimotohno K, Benedicto I and Majano PL: Apolipoprotein E, but not apolipoprotein b, is essential for efficient cell-to-cell transmission of hepatitis C virus. J Virol 89: 9962-9973, 2015.","DOI":"10.1128\/JVI.00577-15"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Hueging K, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, Gumz F, Haid S, Wolk B, Kaderali L and Pietschmann T: Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J Virol 88: 1433-1446, 2014.","DOI":"10.1128\/JVI.01815-13"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Barretto N, Sainz B, Jr., Hussain S and Uprichard SL: Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread. J Virol 88: 5050-5061, 2014.","DOI":"10.1128\/JVI.03241-13"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Graw F, Martin DN, Perelson AS, Uprichard SL and Dahari H: Quantification of hepatitis C virus cell-to-cell spread using a stochastic modeling approach. J Virol 89: 6551-6561, 2015.","DOI":"10.1128\/JVI.00016-15"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Catanese MT, Loureiro J, Jones CT, Dorner M, von Hahn T and Rice CM: Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol 87: 8282-8293, 2013.","DOI":"10.1128\/JVI.01102-13"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Fofana I, Jilg N, Chung RT and Baumert TF: Entry inhibitors and future treatment of hepatitis C. Antiviral Res 104: 136-142, 2014.","DOI":"10.1016\/j.antiviral.2014.02.001"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Zona L, Tawar RG, Zeisel MB, Xiao F, Schuster C, Lupberger J and Baumert TF: CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. Viruses 6: 875-892, 2014.","DOI":"10.3390\/v6020875"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Poumbourios P and Drummer HE: Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents. Antivir Chem Chemother 18: 169-189, 2007.","DOI":"10.1177\/095632020701800402"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Blaising J, Levy PL, Gondeau C, Phelip C, Varbanov M, Teissier E, Ruggiero F, Polyak SJ, Oberlies NH, Ivanovic T, Boulant S and Pecheur EI: Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell Microbiol 15: 1866-1882, 2013.","DOI":"10.1111\/cmi.12155"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C and Rouille Y: Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80: 6964-6972, 2006.","DOI":"10.1128\/JVI.00024-06"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Marino Z, Crespo G, D'Amato M, Brambilla N, Giacovelli G, Rovati L, Costa J, Navasa M and Forns X: Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J Hepatol 58: 415-420, 2013.","DOI":"10.1016\/j.jhep.2012.09.034"},{"key":"67","doi-asserted-by":"crossref","unstructured":"68) Yamashita M, Iida M, Tada M, Shirasago Y, Fukasawa M, Nagase S, Watari A, Ishii-Watabe A, Yagi K and Kondoh M: Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus. J Pharmacol Exp Ther 353: 112-118, 2015.","DOI":"10.1124\/jpet.114.217653"},{"key":"68","doi-asserted-by":"crossref","unstructured":"69) Hopcraft SE and Evans MJ: Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins. Hepatology 62: 1059-1069, 2015.","DOI":"10.1002\/hep.27815"},{"key":"69","doi-asserted-by":"crossref","unstructured":"70) Che P, Tang H and Li Q: The interaction between claudin-1 and dengue viral prM\/M protein for its entry. Virology 446: 303-313, 2013.","DOI":"10.1016\/j.virol.2013.08.009"},{"key":"70","doi-asserted-by":"crossref","unstructured":"71) Gao F, Duan X, Lu X, Liu Y, Zheng L, Ding Z and Li J: Novel binding between pre-membrane protein and claudin-1 is required for efficient dengue virus entry. Biochem Biophys Res Commun 391: 952-957, 2010.","DOI":"10.1016\/j.bbrc.2009.11.172"},{"key":"71","doi-asserted-by":"crossref","unstructured":"72) Tawar RG, Colpitts CC, Lupberger J, El-Saghire H, Zeisel MB and Baumert TF: Claudins and pathogenesis of viral infection. Semin Cell Dev Biol 42: 39-46, 2015.","DOI":"10.1016\/j.semcdb.2015.04.011"},{"key":"72","doi-asserted-by":"crossref","unstructured":"73) Torres-Flores JM and Arias CF: Tight junctions go viral! Viruses 7: 5145-5154, 2015.","DOI":"10.3390\/v7092865"},{"key":"73","doi-asserted-by":"crossref","unstructured":"74) Torres-Flores JM, Silva-Ayala D, Espinoza MA, Lopez S and Arias CF: The tight junction protein JAM-A functions as coreceptor for rotavirus entry into MA104 cells. Virology 475: 172-178, 2015.","DOI":"10.1016\/j.virol.2014.11.016"},{"key":"74","doi-asserted-by":"crossref","unstructured":"75) Coyne CB, Shen L, Turner JR and Bergelson JM: Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host Microbe 2: 181-192, 2007.","DOI":"10.1016\/j.chom.2007.07.003"},{"key":"75","doi-asserted-by":"crossref","unstructured":"76) Greber UF and Gastaldelli M: Junctional gating: the achilles' heel of epithelial cells in pathogen infection. Cell Host Microbe 2: 143-146, 2007.","DOI":"10.1016\/j.chom.2007.08.004"}],"container-title":["Uirusu"],"original-title":["\u5bbf\u4e3b\u4fb5\u5165\u56e0\u5b50Claudin-1\u3092\u6a19\u7684\u3068\u3057\u305f\u6297C\u578b\u809d\u708e\u30a6\u30a4\u30eb\u30b9\u6226\u7565"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsv\/65\/2\/65_245\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T19:16:59Z","timestamp":1568488619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsv\/65\/2\/65_245\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2222\/jsv.65.245","relation":{},"ISSN":["0042-6857","1884-3433"],"issn-type":[{"value":"0042-6857","type":"print"},{"value":"1884-3433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}